Cargando…
Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England
The Omicron variant of SARS-CoV-2 became the globally dominant variant in early 2022. A sub-lineage of the Omicron variant (BA.2) was identified in England in January 2022. Here, we investigated hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) com...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559149/ https://www.ncbi.nlm.nih.gov/pubmed/36229438 http://dx.doi.org/10.1038/s41467-022-33740-9 |
_version_ | 1784807593693151232 |
---|---|
author | Webster, H. H. Nyberg, T. Sinnathamby, M. A. Aziz, N. Abdul Ferguson, N. Seghezzo, G. Blomquist, P. B. Bridgen, J. Chand, M. Groves, N. Myers, R. Hope, R. Ashano, E. Lopez-Bernal, J. De Angelis, D. Dabrera, G. Presanis, A. M. Thelwall, S. |
author_facet | Webster, H. H. Nyberg, T. Sinnathamby, M. A. Aziz, N. Abdul Ferguson, N. Seghezzo, G. Blomquist, P. B. Bridgen, J. Chand, M. Groves, N. Myers, R. Hope, R. Ashano, E. Lopez-Bernal, J. De Angelis, D. Dabrera, G. Presanis, A. M. Thelwall, S. |
author_sort | Webster, H. H. |
collection | PubMed |
description | The Omicron variant of SARS-CoV-2 became the globally dominant variant in early 2022. A sub-lineage of the Omicron variant (BA.2) was identified in England in January 2022. Here, we investigated hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) compared to BA.1 (n = 984,337) in a large cohort study in England. We estimated the risk of hospital attendance, hospital admission or death using multivariable stratified proportional hazards regression models. After adjustment for confounders, BA.2 cases had lower or similar risks of death (HR = 0.80, 95% CI 0.71–0.90), hospital admission (HR = 0.88, 95% CI 0.83–0.94) and any hospital attendance (HR = 0.98, 95% CI 0.95–1.01). These findings that the risk of severe outcomes following infection with BA.2 SARS-CoV-2 was slightly lower or equivalent to the BA.1 sub-lineage can inform public health strategies in countries where BA.2 is spreading. |
format | Online Article Text |
id | pubmed-9559149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-95591492022-10-14 Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England Webster, H. H. Nyberg, T. Sinnathamby, M. A. Aziz, N. Abdul Ferguson, N. Seghezzo, G. Blomquist, P. B. Bridgen, J. Chand, M. Groves, N. Myers, R. Hope, R. Ashano, E. Lopez-Bernal, J. De Angelis, D. Dabrera, G. Presanis, A. M. Thelwall, S. Nat Commun Article The Omicron variant of SARS-CoV-2 became the globally dominant variant in early 2022. A sub-lineage of the Omicron variant (BA.2) was identified in England in January 2022. Here, we investigated hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) compared to BA.1 (n = 984,337) in a large cohort study in England. We estimated the risk of hospital attendance, hospital admission or death using multivariable stratified proportional hazards regression models. After adjustment for confounders, BA.2 cases had lower or similar risks of death (HR = 0.80, 95% CI 0.71–0.90), hospital admission (HR = 0.88, 95% CI 0.83–0.94) and any hospital attendance (HR = 0.98, 95% CI 0.95–1.01). These findings that the risk of severe outcomes following infection with BA.2 SARS-CoV-2 was slightly lower or equivalent to the BA.1 sub-lineage can inform public health strategies in countries where BA.2 is spreading. Nature Publishing Group UK 2022-10-13 /pmc/articles/PMC9559149/ /pubmed/36229438 http://dx.doi.org/10.1038/s41467-022-33740-9 Text en © Crown 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Webster, H. H. Nyberg, T. Sinnathamby, M. A. Aziz, N. Abdul Ferguson, N. Seghezzo, G. Blomquist, P. B. Bridgen, J. Chand, M. Groves, N. Myers, R. Hope, R. Ashano, E. Lopez-Bernal, J. De Angelis, D. Dabrera, G. Presanis, A. M. Thelwall, S. Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England |
title | Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England |
title_full | Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England |
title_fullStr | Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England |
title_full_unstemmed | Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England |
title_short | Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England |
title_sort | hospitalisation and mortality risk of sars-cov-2 variant omicron sub-lineage ba.2 compared to ba.1 in england |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559149/ https://www.ncbi.nlm.nih.gov/pubmed/36229438 http://dx.doi.org/10.1038/s41467-022-33740-9 |
work_keys_str_mv | AT websterhh hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT nybergt hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT sinnathambyma hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT aziznabdul hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT fergusonn hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT seghezzog hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT blomquistpb hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT bridgenj hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT chandm hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT grovesn hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT myersr hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT hoper hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT ashanoe hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT lopezbernalj hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT deangelisd hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT dabrerag hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT presanisam hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland AT thelwalls hospitalisationandmortalityriskofsarscov2variantomicronsublineageba2comparedtoba1inengland |